FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912068031> ?p ?o ?g. }

• W2912068031 endingPage "596" @default.
• W2912068031 startingPage "589" @default.
• W2912068031 abstract "With increasing anti-PD-1 therapy use in patients with melanoma and other tumor types, there is interest in developing early on-treatment biomarkers that correlate with long-term patient outcome. An understanding of the pathologic features of immune-mediated tumor regression is key in this endeavor.Histologic features of immune-related pathologic response (irPR) following anti-PD-1 therapy were identified on hematoxylin and eosin (H&E)-stained slides in a discovery cohort of pre- and on-treatment specimens from n = 16 patients with advanced melanoma. These features were used to generate an irPR score [from 0 = no irPR features to 3 = major pathologic response on biopsy (MPRbx, ≤10% residual viable tumor)]. This scoring system was then tested for an association with objective response by RECIST1.1 and overall survival in a prospectively collected validation cohort of pre- and on-treatment biopsies (n = 51 on-treatment at 4-week timepoint) from melanoma patients enrolled on the nivolumab monotherapy arm of CA209-038 (NCT01621490).Specimens from responders in the discovery cohort had features of immune-activation (moderate-high TIL densities, plasma cells) and wound-healing/tissue repair (neovascularization, proliferative fibrosis) compared to nonresponders, (P ≤ 0.021, for each feature). In the validation cohort, increasing irPR score associated with objective response (P = 0.009) and MPRbx associated with increased overall survival (n = 51; HR 0.13; 95%CI, 0.054-0.31, P = 0.015). Neither tumoral necrosis nor pretreatment histologic features were associated with response. Eight of 16 (50%) of patients with stable disease showed irPR features, two of which were MPRbx, indicating a disconnect between pathologic and radiographic features at the 4-week on-therapy timepoint for some patients.Features of immune-mediated tumor regression on routine H&E-stained biopsy slides from patients with advanced melanoma correlate with objective response to anti-PD-1 and overall survival. An on-therapy biopsy may be particularly clinically useful for informing treatment decisions in patients with radiographic stable disease. This approach is inexpensive, straightforward, and widely available." @default.
• W2912068031 created "2019-02-21" @default.
• W2912068031 creator A5014494747 @default.
• W2912068031 creator A5025100380 @default.
• W2912068031 creator A5034786338 @default.
• W2912068031 creator A5035471137 @default.
• W2912068031 creator A5063104091 @default.
• W2912068031 creator A5071088476 @default.
• W2912068031 creator A5074629137 @default.
• W2912068031 creator A5079599604 @default.
• W2912068031 creator A5084967339 @default.
• W2912068031 creator A5085317448 @default.
• W2912068031 creator A5088644322 @default.
• W2912068031 creator A5090785186 @default.
• W2912068031 creator A5091176592 @default.
• W2912068031 date "2019-04-01" @default.
• W2912068031 modified "2023-10-03" @default.
• W2912068031 title "Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response" @default.
• W2912068031 cites W1498931318 @default.
• W2912068031 cites W1988160404 @default.
• W2912068031 cites W2021179311 @default.
• W2912068031 cites W2099432296 @default.
• W2912068031 cites W2134291074 @default.
• W2912068031 cites W2281666530 @default.
• W2912068031 cites W2299181842 @default.
• W2912068031 cites W2435243879 @default.
• W2912068031 cites W2465860350 @default.
• W2912068031 cites W2615188404 @default.
• W2912068031 cites W2761575992 @default.
• W2912068031 cites W2775456764 @default.
• W2912068031 cites W2798160602 @default.
• W2912068031 cites W2800799386 @default.
• W2912068031 cites W2810879984 @default.
• W2912068031 cites W2867613812 @default.
• W2912068031 cites W2884397450 @default.
• W2912068031 cites W2885119483 @default.
• W2912068031 cites W2890264109 @default.
• W2912068031 cites W2891704612 @default.
• W2912068031 doi "https://doi.org/10.1093/annonc/mdz019" @default.
• W2912068031 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6503625" @default.
• W2912068031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30689736" @default.
• W2912068031 hasPublicationYear "2019" @default.
• W2912068031 type Work @default.
• W2912068031 sameAs 2912068031 @default.
• W2912068031 citedByCount "35" @default.
• W2912068031 countsByYear W29120680312019 @default.
• W2912068031 countsByYear W29120680312020 @default.
• W2912068031 countsByYear W29120680312021 @default.
• W2912068031 countsByYear W29120680312022 @default.
• W2912068031 countsByYear W29120680312023 @default.
• W2912068031 crossrefType "journal-article" @default.
• W2912068031 hasAuthorship W2912068031A5014494747 @default.
• W2912068031 hasAuthorship W2912068031A5025100380 @default.
• W2912068031 hasAuthorship W2912068031A5034786338 @default.
• W2912068031 hasAuthorship W2912068031A5035471137 @default.
• W2912068031 hasAuthorship W2912068031A5063104091 @default.
• W2912068031 hasAuthorship W2912068031A5071088476 @default.
• W2912068031 hasAuthorship W2912068031A5074629137 @default.
• W2912068031 hasAuthorship W2912068031A5079599604 @default.
• W2912068031 hasAuthorship W2912068031A5084967339 @default.
• W2912068031 hasAuthorship W2912068031A5085317448 @default.
• W2912068031 hasAuthorship W2912068031A5088644322 @default.
• W2912068031 hasAuthorship W2912068031A5090785186 @default.
• W2912068031 hasAuthorship W2912068031A5091176592 @default.
• W2912068031 hasBestOaLocation W29120680311 @default.
• W2912068031 hasConcept C121608353 @default.
• W2912068031 hasConcept C125473707 @default.
• W2912068031 hasConcept C126322002 @default.
• W2912068031 hasConcept C142724271 @default.
• W2912068031 hasConcept C143998085 @default.
• W2912068031 hasConcept C185592680 @default.
• W2912068031 hasConcept C204232928 @default.
• W2912068031 hasConcept C2775934546 @default.
• W2912068031 hasConcept C2777658100 @default.
• W2912068031 hasConcept C2777701055 @default.
• W2912068031 hasConcept C2780030458 @default.
• W2912068031 hasConcept C2781197716 @default.
• W2912068031 hasConcept C502942594 @default.
• W2912068031 hasConcept C55493867 @default.
• W2912068031 hasConcept C71924100 @default.
• W2912068031 hasConcept C72563966 @default.
• W2912068031 hasConcept C90924648 @default.
• W2912068031 hasConceptScore W2912068031C121608353 @default.
• W2912068031 hasConceptScore W2912068031C125473707 @default.
• W2912068031 hasConceptScore W2912068031C126322002 @default.
• W2912068031 hasConceptScore W2912068031C142724271 @default.
• W2912068031 hasConceptScore W2912068031C143998085 @default.
• W2912068031 hasConceptScore W2912068031C185592680 @default.
• W2912068031 hasConceptScore W2912068031C204232928 @default.
• W2912068031 hasConceptScore W2912068031C2775934546 @default.
• W2912068031 hasConceptScore W2912068031C2777658100 @default.
• W2912068031 hasConceptScore W2912068031C2777701055 @default.
• W2912068031 hasConceptScore W2912068031C2780030458 @default.
• W2912068031 hasConceptScore W2912068031C2781197716 @default.
• W2912068031 hasConceptScore W2912068031C502942594 @default.
• W2912068031 hasConceptScore W2912068031C55493867 @default.
• W2912068031 hasConceptScore W2912068031C71924100 @default.
• W2912068031 hasConceptScore W2912068031C72563966 @default.

• next